Search results
Results from the WOW.Com Content Network
In October 2020, the U.S. FDA approved the combination of nivolumab with ipilimumab for the first-line treatment of adults with malignant pleural mesothelioma that cannot be removed by surgery. [32] This is the first drug regimen approved for mesothelioma in sixteen years and the second FDA-approved systemic therapy for mesothelioma. [32]
granted for three indications: HER2-positive breast cancer with prior anti-HER2-based treatment; HER2 low (IHC 1+ or IHC 2+/ISH) breast cancer; and non-small cell lung cancer with an activating HER2 mutation Dupilumab: Regeneron Pharmaceuticals: granted for two indications: eosinophilic esophagitis; and atopic dermatitis: Ivosidenib: Servier ...
Dostarlimab was approved for the treatment of endometrial cancer in both the United States and the European Union in April 2021. [ 5 ] [ 6 ] [ 11 ] [ 8 ] [ 12 ] Based on the Garnet trial, dostarlimab gained accelerated approval from the US Food and Drug Administration (FDA) in April 2021, [ 6 ] and full approval in February 2023.
The approval allows the use of the cancer drug, Rybrevant, in combination with J&J's existing drug, lazertinib, as a first-line treatment for non-small cell lung cancer (NSCLC) patients with a ...
The FDA bestows a Breakthrough Therapy designation to Syndax's (SNDX) revumenib for treating patients with relapsed/refractory acute leukemia harboring a KMT2A rearrangement. Stock up.
A: In 2024, precision cancer treatment made big strides with many new drug approvals by the FDA, specifically for treatments guided by specific biomarkers, which means treatments can be more ...
Talimogene laherparepvec is delivered by injecting it directly into tumors, thereby creating a systemic anti-tumor immune response. [2]In the US, talimogene laherparepvec is FDA approved to treat Stage IIIb-IVM1c melanoma patients for whom surgical intervention is not appropriate and with tumors which can be directly injected; the EMA approved population in Europe is for Stage IIIb-IVM1a.
In August 2017, the FDA granted approval for the use of tisagenlecleucel in people with acute lymphoblastic leukemia. [ 21 ] [ 22 ] [ 23 ] According to Novartis, the treatment will be administered at specific medical centers where staff have been trained to manage possible reactions to this new type of treatment.